The American Journal of Medicine
Volume 120, Issue 8 , Pages 685-692 , August 2007

Impact of Acute Beta-Blocker Therapy for Patients with Non–ST-Segment Elevation Myocardial Infarction

  • Chadwick D. Miller, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Matthew T. Roe, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Jyotsna Mulgund, MS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • James W. Hoekstra, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Renato Santos, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Charles V. Pollack Jr., MD, MA

      Affiliations

    • Pennsylvania Hospital, University of Pennsylvania School of Medicine, Philadelphia
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • W. Brian Gibler, MD

      Affiliations

    • University of Cincinnati College of Medicine, Cincinnati, Ohio.
    • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationRequests for reprints should be addressed to Eric Peterson, MD, MPH, Duke Clinical Research Institute, 2400 Pratt Street, Room 7009, Durham, NC 27705.

References 

  1. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66
  2. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI) (A randomised placebo-controlled international trial). Eur Heart J. 1985;6:199–226
  3. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction (Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study). Circulation. 1991;83:422–437
  4. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  5. Chen ZM, Pan HC, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–1632
  6. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology American Heart Association Committee on the Management of Patients with Unstable Angina ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  7. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  8. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22
  9. Hjalmarson A, Goldstein S, Fagerberg B, et al. MERIT-HF Study Group Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295–1302
  10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  11. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–2199
  12. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525–530
  13. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623–629
  14. Chen J, Radford MJ, Wang Y, et al. Are β-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction?. Arch Intern Med. 2000;160:947–952
  15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489–497
  16. Steg PG, Dabbous OH, Feldman LJ, et al. Global Registry of Acute Coronary Events Investigators Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494–499
  17. Forman DE, Bernal JL, Wei JY. Management of acute myocardial infarction in the very elderly. Am J Med. 1992;93:315–326
  18. Bradley EH, Holmboe ES, Mattera JA, et al. A qualitative study of increasing beta-blocker use after myocardial infarction: why do some hospitals succeed?. JAMA. 2001;285:2604–2611
  19. Krumholz HM, Anderson JL, Brooks NH, et al. American College of Cardiology/American Heart Association Task Force on Performance Measures Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on performance measures (writing committee to develop performance measures on ST-elevation and non-ST-elevation myocardial infarction). Circulation. 2006;113:732–761

 CRUSADE is funded by the Schering-Plough Corporation. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership provides additional funding support. Millennium Pharmaceuticals, Inc. also funded this work.

PII: S0002-9343(07)00413-5

doi: 10.1016/j.amjmed.2007.04.016

The American Journal of Medicine
Volume 120, Issue 8 , Pages 685-692 , August 2007

Article Tools

* Image Usage & Resolution